EMEA-002519-PIP02-18
Key facts
| Active substance |
2-(2-(3-Butoxy-phenyl)-ethylamino)-N,N-dimethyl-acetamide hydrochloride
|
| Therapeutic area |
Psychiatry
|
| Decision number |
P/0215/2019
|
| PIP number |
EMEA-002519-PIP02-18
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of schizophrenia
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Newron Pharmaceuticals SpA
E-mail: ravi@anand.ch |
| Decision type |
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)
|